Patents by Inventor Bruce A. Beutler

Bruce A. Beutler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060257411
    Abstract: Compositions and methods are provided for screening and identifying compounds which modulate signaling of toll-like receptor 4 (TLR4) pathway via CD14 and a ligand. Methods are provided for treatment of various disease states such as inflammation or autoimmune disease in mammalian subjects by modulating toll-like receptor 4 (TLR4) pathway signaling via CD14 and a ligand. Transgenic non-human animals and methods for developing transgenic non-human animals are provided wherein the transgenic non-human animals comprise a loss-of-function mutation in the CD14 gene.
    Type: Application
    Filed: May 4, 2006
    Publication date: November 16, 2006
    Inventors: Bruce Beutler, Zhengfan Jiang
  • Patent number: 7029861
    Abstract: The present invention describes a mutant TLR-4 in mice that does not recognize endotoxin and therefore does not stimulate the secretion of TNF from macrophages. Methods of detecting the mutation are provided; as are methods screening for drugs that may stimulate TNF production. Finally methods of incorporating and expressing the mutant TLR-4 genes into a host cell are contemplated.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: April 18, 2006
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bruce A. Beutler, Alexander Poltorak
  • Patent number: 6046309
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 4, 2000
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 6019969
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 1, 2000
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5989836
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 23, 1999
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5925548
    Abstract: Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: July 20, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bruce A. Beutler, Flavia M. Bazzoni
  • Patent number: 5863535
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 26, 1999
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5849873
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5817763
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 6, 1998
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5770402
    Abstract: Disclosed are novel nucleic acid and peptide compositions comprising a constitutively-expressed CC chemokine. Also disclosed are methods of use for MIP-1.gamma. amino acid sequences and the DNA segments which encode them in the stimulation of an immune response, the production of limited pyrexia, the treatment of proliferative cell disorders and T-cell mediated diseases, and the prophylaxis of bacterial sepsis in an animal.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: June 23, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bruce A. Beutler, Alexander N. Poltorak
  • Patent number: 5760186
    Abstract: Antibodies to an inflammatory cytokine are disclosed. The inflammatory cytokine has been isolated from cells that have been incubated with a stimulator material and comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5741484
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 21, 1998
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5628148
    Abstract: A guide pin and conical guide pin receptor for aligning a door relative to a door frame or other stable grounded device. The pin and receptor align the door from horizontal misalignment and radially throughout 360.degree. relative to the axis of the pin receptor. In aligning the door, interfitting elements on the door and door frame are aligned including such elements as comprise key actuated interlocking switch systems.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: May 13, 1997
    Inventor: Bruce Beutler
  • Patent number: 5616688
    Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
    Type: Grant
    Filed: March 7, 1994
    Date of Patent: April 1, 1997
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
  • Patent number: 5447851
    Abstract: The invention relates generally to DNA sequences encoding chimeric polypeptides comprising extracellular portions of cytokine receptor polypeptides attached to a sequence encoding portions of IgG polypeptides. The invention relates generally, as well, to DNA sequences encoding chimeric polypeptides comprising extracellular portions of cytokine receptor polypeptides attached through oligomers encoding specifically cleavable peptide linkers to a sequence encoding portions of IgG heavy chain polypeptides More specifically, the invention relates to a construction in which a cDNA sequence encoding the extracellular domain of the human 55 kD TNF receptor is attached through an oligomer encoding a thrombin-sensitive peptide linker to a sequence encoding the F.sub.c portion and hinge region of a mouse IgGl heavy chain.
    Type: Grant
    Filed: April 2, 1992
    Date of Patent: September 5, 1995
    Assignee: Board of Regents, The University of Texas System
    Inventors: Bruce A. Beutler, Karsten Peppel, David F. Crawford